European Child & Adolescent Psychiatry

, Volume 19, Issue 4, pp 353–364 | Cite as

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

  • Stephen V. FaraoneEmail author
  • Jan Buitelaar
Original Contribution


Stimulants used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among stimulants are hindered by the absence of direct comparative trials. The goal of this work was to compare the efficacy of methylphenidate and amfetamine formulations through a meta-analysis of double-blind placebo-controlled trials. We analyzed recent published literature on the stimulant therapy of ADHD to describe the variability of drug–placebo effect sizes. A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD in children and adolescents published after 1979. Meta-analysis regression assessed the influence of medication type and study design features on medication effects. Twenty-three trials met criteria and were included in this meta-analysis. These trials studied 11 drugs using 19 different outcome measures of hyperactive, inattentive, or impulsive behavior. We found significant differences between amfetamine and methylphenidate products, even after correcting for study design features that might have confounded the results. Our analyses indicate that effect sizes for amfetamine products are significantly, albeit moderately, greater than those for methylphenidate. We found that most measures of effect from all studies were statistically significant. Our findings suggest that amfetamine products may be moderately more efficacious than methylphenidate products, even after controlling for potentially confounding study design features. This difference in effect size may be due to differences between amfetamine and methylphenidate in the molecular mechanisms involved in facilitating the dopaminergic neurotransmission.


ADHD Medications Efficacy Effect size Meta-analysis 



This work was supported by Shire Development.

Conflict of interest statement

Dr. Stephen V. Faraone is/has been a consultant for, receives/d research support from, is/has been a speaker for, or is/has been on the advisory board for the following pharmaceutical companies: McNeil, Pfizer, Shire, Eli Lilly and Company, and the Novartis Corporation. Dr. Jan K. Buitelaar is/has been a consultant for, receives/d research support from, is/has been a speaker for, or is/has been on the advisory board for the following pharmaceutical companies: Janssen Cilag BV, Eli Lilly and Company, UCB, Shire, Servier, Bristol-Myer Squibb, Organon, and Bioproject.


  1. 1.
    Arnold L (2000) Methylphenidate vs. amphetamine: comparative review. J Atten Disord 3:200–211CrossRefGoogle Scholar
  2. 2.
    Arnold LE, Christopher J, Huestis R, Smeltzer DJ (1978) Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction. Arch Gen Psychiatry 35:463–473PubMedGoogle Scholar
  3. 3.
    Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495CrossRefPubMedGoogle Scholar
  4. 4.
    Biederman J, Lopez FA, Boellner SW, Chandler MC (2002) A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 in children with attention deficit hyperactivity disorder. Pediatrics 110:258–266CrossRefPubMedGoogle Scholar
  5. 5.
    Cohen J (1988) Statistical power analysis for the behavioral sciences. Erlbaum, HillsdaleGoogle Scholar
  6. 6.
    Colditz GA, Miller JN, Mosteller F (1988) Measuring gain in the evaluation of medical technology. The probability of a better outcome. Int J Technol Assess Health Care 4:637–642CrossRefPubMedGoogle Scholar
  7. 7.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B (2006) Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 118:e704–e710CrossRefPubMedGoogle Scholar
  8. 8.
    Dersimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  9. 9.
    Dlugos A, Freitag C, Hohoff C, Mcdonald J, Cook EH, Deckert J, De Wit H (2007) Norepinephrine transporter gene variation modulates acute response to d-amphetamine. Biol Psychiatry 61:1296–1305CrossRefPubMedGoogle Scholar
  10. 10.
    Duval S, Tweedie R (2000) A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc 95:89–98CrossRefGoogle Scholar
  11. 11.
    Efron D, Jarman F, Barker M (1997) Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100:E6CrossRefPubMedGoogle Scholar
  12. 12.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629–634Google Scholar
  13. 13.
    Elia J, Borcherding BG, Rapoport JL, Keysor CS (1991) Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 36:141–155CrossRefPubMedGoogle Scholar
  14. 14.
    Elia J, Welsh P, Gullota C, Rapoport J (1993) Classroom academic performance: Improvement with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatry Allied Disciplines 34:785–804CrossRefGoogle Scholar
  15. 15.
    Faraone S, Biederman J (2002) Efficacy of adderall, for attention-deficit/hyperactivity disorder: a meta-analysis. J Atten Disord 6:69–75CrossRefPubMedGoogle Scholar
  16. 16.
    Faraone S, Short E, Biederman J, Findling RL, Roe CM, Manos M (2002) Efficacy of Adderall and Methylphenidate in attention deficit hyperactivity disorder: a drug–placebo and drug–drug response curve analysis of a naturalistic study. Int J Neuropsychopharmacol 5:121–129CrossRefPubMedGoogle Scholar
  17. 17.
    Faraone SV, Biederman J, Roe CM (2002) Comparative efficacy of adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 22:468–473CrossRefPubMedGoogle Scholar
  18. 18.
    Faraone SV, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F, Glatt S (2005) Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug–placebo response curve analysis. Behav Brain Funct 1:16CrossRefPubMedGoogle Scholar
  19. 19.
    Faraone SV, Biederman J, Spencer TJ, Aleardi M (2006) Comparing the efficacy of medications for ADHD using meta-analysis. Medscape Gen Med E J 8:4Google Scholar
  20. 20.
    Faraone SV, Biederman J, Spencer TJ, Wilens TE (2000) The drug–placebo response curve: a new method for assessing drug effects in clinical trials. J Clin Psychopharmacol 20:673–679CrossRefPubMedGoogle Scholar
  21. 21.
    Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J (2001) Efficacy of adderall and methylphenidate in attention-deficit/hyperactivity disorder: a drug–placebo and drug–drug response curve analysis. J Child Adolesc Psychopharmacol 11:171–180CrossRefPubMedGoogle Scholar
  22. 22.
    Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104–113PubMedGoogle Scholar
  23. 23.
    Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J (2004) Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol 54:24–29CrossRefGoogle Scholar
  24. 24.
    Green C (1996) Methylphenidate vs dexamphetamine: a clinical audit. J Paediatr Child Health 32:470CrossRefPubMedGoogle Scholar
  25. 25.
    Greenhill LL, Findling RL, Swanson JM (2002) A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:E39CrossRefPubMedGoogle Scholar
  26. 26.
    Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, Mcclellan J, Rue D, Shaw JA, Stock S, Kroeger K (2001) Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 40:1352–1355CrossRefPubMedGoogle Scholar
  27. 27.
    Hanley JA, Mcneil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMedGoogle Scholar
  28. 28.
    Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic Press, OrlandoGoogle Scholar
  29. 29.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedGoogle Scholar
  30. 30.
    Huber PJ (1967) The behavior of maximum likelihood estimates under non-standard conditions. Proc Fifth Berkeley Symp Math Stat Probab 1:221–233Google Scholar
  31. 31.
    Hunter JE, Schmidt FL (1990) Methods of meta-analysis: correcting error and bias in research findings. Sage, Newbury ParkGoogle Scholar
  32. 32.
    Kraemer HC, Kupfer DJ (2006) Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 59:990–996CrossRefPubMedGoogle Scholar
  33. 33.
    Manos MJ, Short EJ, Findling RL (1999) Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 38:813–819CrossRefPubMedGoogle Scholar
  34. 34.
    Mcgraw KO, Wong SP (1992) A common language effect size statistic. Psychol Bull 111:361–365CrossRefGoogle Scholar
  35. 35.
    Patrick KS, Caldwell RW, Ferris RM, Breese GR (1987) Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 241:152–158PubMedGoogle Scholar
  36. 36.
    Pelham W, Greenslade K, Vodde-Hamilton M, Murphy D, Greenstein J, Gnagy E, Guthrie K, Hoover M, Dahl R (1990) Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86:226–237PubMedGoogle Scholar
  37. 37.
    Pliszka SR, Browne RG, Olvera RL, Wynne SK (2000) A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39:619–626CrossRefPubMedGoogle Scholar
  38. 38.
    Schachter HM, Pham B, King J, Langford S, Moher D (2001) How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165:1475–1488PubMedGoogle Scholar
  39. 39.
    Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639–677CrossRefPubMedGoogle Scholar
  40. 40.
    Short EJ, Manos MJ, Findling RL, Schubel EA (2004) A prospective study of stimulant response in preschool children: insights from ROC analyses. J Am Acad Child Adolesc Psychiatry 43:251–259CrossRefPubMedGoogle Scholar
  41. 41.
    Spencer T, Biederman J, Wilens T (2000) Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:77–97PubMedGoogle Scholar
  42. 42.
    Stata Corporation (2001) Stata user’s guide: release 7.0. Stata Corporation, College StationGoogle Scholar
  43. 43.
    Thornburg JE, Moore KE (1973) The relative importance of dopaminergic and noradrenergic neuronal systems for the stimulation of locomotor activity induced by amphetamine and other drugs. Neuropharmacology 12:853–866CrossRefPubMedGoogle Scholar
  44. 44.
    Tiihonen J, Hallikainen T, Ryynanen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, Toivonen P, Wahlbeck K, Putkonen A (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54:1241–1248CrossRefPubMedGoogle Scholar
  45. 45.
    Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002) Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 6:S31–S43PubMedGoogle Scholar
  46. 46.
    Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:RC121PubMedGoogle Scholar
  47. 47.
    Wilens T, Mcburnett K, Bukstein O, Mcgough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper K, Lynch JM (2006) Multisite, controlled trial of OROS® methylphenidate (CONCERTA®) in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160:82–90CrossRefPubMedGoogle Scholar
  48. 48.
    Wilson HK, Cox DJ, Merkel RL, Moore M, Coghill D (2006) Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol 21:797–807CrossRefPubMedGoogle Scholar
  49. 49.
    Wolraich M, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, Mcburnett K, Bukstein O, August G (2001) Randomized controlled trial of OROS methylphenidate qd in children with attention deficit/hyperactivity disorder. Pediatrics 108:883–892CrossRefPubMedGoogle Scholar
  50. 50.
    Zeiner P, Bryhn G, Bjercke C, Truyen K, Strand G (1999) Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatr 88:298–303CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Departments of Psychiatry and Neuroscience & PhysiologySUNY Upstate Medical UniversitySyracuseUSA
  2. 2.Department of PsychiatryRadboud University Nijmegen Medical CenterNijmegenThe Netherlands
  3. 3.Departments of Psychiatry and Behavioral SciencesSUNY Upstate Medical University (SVF)SyracuseUSA

Personalised recommendations